与成年人患有Clostridioides difficile感染的vancomycin相比,ibezapolstat的有效性,安全性,药理动力学和相关的微生物组变化:一个2b期,随机,双盲,主动受控,多中心研究
Taryn A Eubank1, Jinhee Jo1, M Jahangir Alam1
1Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
The Lancet. Microbe
|June 14, 2025
概括
伊贝扎波尔斯塔特在治疗Clostridioides difficile感染方面表现有前途,在2b期试验中,其安全性和有效性与万科米辛相似. 建议对这种针对C. difficile的新型抗生素进行进一步开发.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 困难类闭膜炎感染 (CDI) 是一个重要的医疗保健挑战,治疗选择有限.
- 抗生素耐药性和复发率需要开发新的CDI治疗方法.
研究的目的:
- 为了评估ibezapolstat的安全性,疗效,药理动力学和微生物组影响,与治疗CDI的万科米辛相比.
- 评估ibezapolstat作为C. difficile感染的新治疗剂的潜力.
主要方法:
- 一项2b期,随机,双盲,主动控制的研究,涉及32名患有CDI的成年参与者.
- 参与者接受了口服伊贝扎波尔斯塔特 (450毫克两次) 或口服万科米辛 (125毫克四次) 10天.
- 主要终点是治疗后至少48小时保持初始临床治愈.
主要成果:
- 在ibezapolstat组的94% (15/16) 和万科米辛组的100% (14/14) 实现了初始临床治愈.
- 伊贝扎波尔斯塔特表现出耐受性良好的安全性,与万科米辛可比,没有与药物相关的严重不良事件.
- 这项研究提供了ibezapolstat在治疗C. difficile感染中的疗效和安全性的初步证据.
结论:
- 伊贝扎波尔斯塔特是一种选择性格拉姆阳性抗生素,具有治疗初始CDI和预防复发的潜力.
- 需要进行进一步的临床试验,以充分确定ibezapolstat在CDI管理中的作用.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
111
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
111
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130


